The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Daratumumab Access Differences Highlight Potential Racial Disparities in MM Care
This retrospective chart review investigated outcomes among patients who are White or Black on a daratumumab regimen for multiple myeloma (MM).
QOL Tool Valuable in Identifying Patients’ Chief Concerns
A tool used to identify primary concerns of patients was helpful in identifying main worries about time, as it related to quality of life (QOL), and held value for patients and clinicians.
Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS
Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
Rare MM Case Underscores Need to Consider Differential Diagnoses
In this case report, a 50-year-old female patient, with a family history of lung cancer, received a diagnosis of multiple myeloma (MM) following presentation with an apical lung mass.
NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression
Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment
Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.
With Multiple Myeloma, Caregivers May See More Mental Health Effects Than Patients
A study in Blood Advances highlights the toll that a terminal diagnosis can have on everyone around a patient.
Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma
Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.
Age, Infection, Cardiac Disease Linked to Early Death for Patients With Newly Diagnosed Multiple Myeloma
Results from a registry study of patients from Australia and New Zealand show that 9.1% of patients with a new diagnosis of multiple myeloma die within a year of diagnosis, and infection contributed to early death in 38% of cases in which a cause of death was reported.
Index Finds Half of MM, CLL Patients in Study Had Financial Difficulty
Financial difficulty during treatment for multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) was associated with lower levels of education, incomes below $60,000, and multiple comorbidities.
Review of MM Treatment Landscape Compares Clinical Trials With Real-World Results
Real-world patients often differ from those eligible for clinical trials, and comparing results in both populations is a key step in fine-tuning treatment strategies for multiple myeloma.
Exploring Genomic and Transcriptomic Changes Throughout Multiple Myeloma Progression
Whole-exome and RNA sequencing of early and late multiple myeloma tumor samples aimed to provide insight into disease drivers and phenotypes.
Discussing The Future of the RRMM Treatment Landscape
Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.
Improving Payer Education on RRMM Therapy
Professional experts offer suggestions on how payers can be further educated on RRMM treatment.
How Do IMiDs Fare In Comparison With Emerging RRMM Treatment Options?
Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy.
Interim Phase 2 Trial Results Show Quadruplet Regimen Tolerable, Effective in MM
Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).
Ways Institutions Can Support RRMM Treatment Selection
Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.
Using Lenalidomide and Pomalidomide in RRMM Management
Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.
Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma
Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.
Review Highlights Nanomedicine as Potential Drug Delivery Strategy in Multiple Myeloma
A recent review summarized the current knowledge and treatment paradigm of multiple myeloma, including recent advances and challenges in nanomedicine.
Vitamin D Provides Therapeutic Benefit Among Patients With MM, Review Says
A literature review revealed that supplementation with vitamin D could provide therapeutic benefits for patients with multiple myeloma (MM) who are undergoing chemotherapy. However, more research is needed to confirm findings.
Preferred IMiDs Regimens Based on Line of Therapy
Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.
What Factors Into IMiDs Treatment Selection for Patients With RRMM?
Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.
IMiDs and Triplet Regimens in MM and RRMM Therapy
Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.
RRMM: An Overview
Joshua Richter, MD, and Jonathan L. Kaufman, MD, define and provide a basic understanding of relapsed/refractory multiple myeloma (RRMM).
High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study
As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.
Low Socioeconomic Status May Account for Ethnic Survival Disparities in MM
The researchers found that socioeconomic status likely drives survival disparities between Hispanic patients and non-Hispanic whites (NHWs). They also found that, while both underserved populations, Hispanics and non-Hispanic blacks have different survival outcomes compared with NHWs.
Is There a Possibility of a Cure in Multiple Myeloma?
Multiple myeloma has historically been considered a chronic disease, even as newer treatments have greatly improved rates of survival for the disease.
Myelofibrosis May Predict Extramedullary Disease in MM
The researchers found that extramedullary disease at diagnosis was significantly more common in patients with bone marrow fibrosis.
Radiomics-Based Models Can Accurately Diagnose MM and Bone Metastases, Study Finds
Differentiation between multiple myeloma (MM) and bone metastases from other cancers can be difficult, but radiomics-based models have potential to improve diagnostic accuracy.
2 Clarke Drive Cranbury, NJ 08512